EFTR
eFFECTOR Therapeutics, Inc. · Healthcare
No insider bought or sold eFFECTOR Therapeutics, Inc. in the last 12 months
EFTR over the last year
Prices for EFTR aren't in yet.
EFTR after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
22 insider filings since 2021, newest first
Sr One Capital Management, LLC · 10% owner
Presidio Management Group X LLC · 10% owner
Presidio Management Group X LLC · 10% owner
Presidio Management Group X LLC · 10% owner
Presidio Management Group X LLC · 10% owner
Presidio Management Group X LLC · 10% owner
Presidio Management Group X LLC · 10% owner
Presidio Management Group X LLC · 10% owner
Christopher B Ehrlich · Director
Christopher B Ehrlich · Director
Jonathan D Root · Director and 10% owner
Presidio Management Group X LLC · 10% owner
Jonathan D Root · Director and 10% owner
Presidio Management Group X LLC · 10% owner
Jonathan D Root · Director and 10% owner
Presidio Management Group X LLC · 10% owner
Jonathan D Root · Director and 10% owner
Presidio Management Group X LLC · 10% owner
Jonathan D Root · Director and 10% owner
Presidio Management Group X LLC · 10% owner
Jonathan D Root · Director and 10% owner
Presidio Management Group X LLC · 10% owner
About eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.